ReviewAnnals of medicine2025
Triptolide-mediated immunomodulation of macrophages: from pathophysiology to therapy.
Review in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Nebulized macrophage membrane-engineered triptolide liposomes for Siglec-10/CD24-mediated therapeutic targeting in lung cancer.International journal of pharmaceutics: X · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTriptolide (TP), a potent bioactive compound from the Chinese herb
objectiveThis review summarizes the immunomodulatory mechanisms of TP on macrophage function, with a focus on its therapeutic potential in diverse diseases. We also explore strategies to mitigate TP's toxicity, including formulation enhancements, targeted delivery, ligand conjugation, and structural modifications. Finally, we highlight the therapeutic utility and clinical progress of TP derivatives, offering insights into their broad clinical applications.
resultsTP modulates macrophage migration, polarization, phagocytosis, and the production of cytokines and chemokines, thereby alleviating various macrophage-centric diseases. Strategies to reduce TP's toxicity not only mitigate systemic adverse effects but also enhance therapeutic efficacy through macrophage-targeted delivery. The clinical progress of TP derivatives demonstrates their broad therapeutic potential.
conclusionTP's macrophage-targeted immunomodulation shows promising therapeutic potential for macrophage-centric diseases. However, its limited clinical use due to poor water solubility and significant toxicity highlights the need for further research to develop effective toxicity-reduction strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.